Tezspire Hits All Endpoints in Eosinophilic Esophagitis Trial
AMGN sits 65% above its 52-week low of $269.77.
Summary
AstraZeneca's Tezspire, co-developed with Amgen, met all primary and secondary endpoints in a late-stage trial for eosinophilic esophagitis, a chronic inflammatory esophagus disorder. The safety profile was consistent with approved indications. This expands Tezspire's potential beyond severe asthma into a new indication with significant unmet need. The positive data could support regulatory submissions and broaden the drug's market opportunity. Amgen shares the economics of Tezspire with AstraZeneca, so this success directly benefits Amgen's pipeline. Watch for detailed efficacy data and any announcement of regulatory filing plans.
At the time of this announcement, AMGN was trading at $443.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $239.1B. The 52-week trading range was $269.77 to $447.03. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.